Multisession radiosurgery for intracranial meningioma treatment: study protocol of a single arm, monocenter, prospective trial.

Cavernous sinus meningioma Fractionated radiosurgery Hypofractionated stereotactic radiotherapy Intracranial meningioma Large meningioma Multisession radiosurgery Neurological function preservation Optic pathway meningioma Radiosurgery

Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
30 Jan 2020
Historique:
received: 18 11 2019
accepted: 21 01 2020
entrez: 1 2 2020
pubmed: 1 2 2020
medline: 21 10 2020
Statut: epublish

Résumé

Single session radiosurgery represents a widely accepted treatment for intracranial meningiomas. However, this approach could involve a high risk of treatment-related complications when applied to large volume lesions. In these cases and for those not suitable for surgical resection, radiosurgery in multisession setting could represents a viable option. The literature results are reassuring in terms of correlated adverse events as well as in terms of tumor control. However, no prospective long-term results are available. In this scenario, we design a prospective monocentric phase II study, in order to verify the safety of a multisession radiosurgery schedule delivering 25 Gy in 5 daily fractions. Patients diagnosed with large and/or near to critical structures, intracranial meningiomas have been treated by means of multisession radiosurgery in both exclusive and postoperative settings. The primary study aim is safety that has been being prospectively scored based on international scales, including NCI Common Toxicity criteria, version 4.03, Barrow Neurological Institute pain intensity score, Barrow Neurological Institute facial numbness score and House-Brackmann Facial Nerve Grading System for qualitative analysis. Secondary aim is treatment efficacy in terms of local control that has been being assessed on volumetric analysis. This is the first prospective phase II trial on multisession radiosurgery for large and/or near to critical structures intracranial meningiomas. If positive results will be found, this study could represent the starting point for a phase III trial exploring the role of multisession radiosurgery in the exclusive and postoperative radiation therapy treatment of intracranial meningiomas. Trial registration: clinicaltrials.gov platform (Multisession Radiosurgery in Large Meningiomas -MuRaLM- identifier NCT02974127). Registered: November 28, 2016. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02974127?term=radiosurgery&cond=Intracranial+Meningioma&draw=2&rank=1.

Sections du résumé

BACKGROUND BACKGROUND
Single session radiosurgery represents a widely accepted treatment for intracranial meningiomas. However, this approach could involve a high risk of treatment-related complications when applied to large volume lesions. In these cases and for those not suitable for surgical resection, radiosurgery in multisession setting could represents a viable option. The literature results are reassuring in terms of correlated adverse events as well as in terms of tumor control. However, no prospective long-term results are available. In this scenario, we design a prospective monocentric phase II study, in order to verify the safety of a multisession radiosurgery schedule delivering 25 Gy in 5 daily fractions.
METHODS METHODS
Patients diagnosed with large and/or near to critical structures, intracranial meningiomas have been treated by means of multisession radiosurgery in both exclusive and postoperative settings. The primary study aim is safety that has been being prospectively scored based on international scales, including NCI Common Toxicity criteria, version 4.03, Barrow Neurological Institute pain intensity score, Barrow Neurological Institute facial numbness score and House-Brackmann Facial Nerve Grading System for qualitative analysis. Secondary aim is treatment efficacy in terms of local control that has been being assessed on volumetric analysis.
DISCUSSION CONCLUSIONS
This is the first prospective phase II trial on multisession radiosurgery for large and/or near to critical structures intracranial meningiomas. If positive results will be found, this study could represent the starting point for a phase III trial exploring the role of multisession radiosurgery in the exclusive and postoperative radiation therapy treatment of intracranial meningiomas.
TRIAL REGISTRATION BACKGROUND
Trial registration: clinicaltrials.gov platform (Multisession Radiosurgery in Large Meningiomas -MuRaLM- identifier NCT02974127). Registered: November 28, 2016. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02974127?term=radiosurgery&cond=Intracranial+Meningioma&draw=2&rank=1.

Identifiants

pubmed: 32000819
doi: 10.1186/s13014-020-1478-7
pii: 10.1186/s13014-020-1478-7
pmc: PMC6993396
doi:

Banques de données

ClinicalTrials.gov
['NCT02974127']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Références

Neurosurgery. 1998 Sep;43(3):405-13; discussion 413-4
pubmed: 9733295
Neurology. 2013 Feb 19;80(8):747-53
pubmed: 23390169
Neurosurgery. 2004 Dec;55(6):1371-3
pubmed: 15574218
Neurooncol Pract. 2019 Sep;6(5):346-353
pubmed: 31555449
J Neurosurg. 2005 Jan;102 Suppl:59-70
pubmed: 15662783
Br J Neurosurg. 2019 Jul 9;:1-6
pubmed: 31284785
J Neurooncol. 2019 Jul;143(3):597-604
pubmed: 31119480
Acta Neurochir (Wien). 2009 May;151(5):447-52; discussion 452
pubmed: 19337685
J Neurosurg. 2011 May;114(5):1392-8
pubmed: 21128736
Neurosurg Focus. 2007;23(6):E11
pubmed: 18081476
Neurosurgery. 2011 Nov;69(5):1116-22; discussion 1122-3
pubmed: 21971489
Stereotact Funct Neurosurg. 2009;87(2):120-7
pubmed: 19246961
Neuro Oncol. 2019 Jan 1;21(1):26-36
pubmed: 30137421
Neurosurgery. 2018 Dec 1;83(6):1128-1142
pubmed: 29554317
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1013-9
pubmed: 10863073
Radiat Oncol. 2009 Oct 14;4:42
pubmed: 19828022
J BUON. 2010 Jan-Mar;15(1):68-73
pubmed: 20414930
Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60
pubmed: 18300891
Crit Rev Oncol Hematol. 2017 May;113:122-134
pubmed: 28427502
Neurosurgery. 2009 Feb;64(2 Suppl):A7-13
pubmed: 19165077
Springerplus. 2015 Jan 30;4:37
pubmed: 25674497
Neurol Sci. 2009 Dec;30(6):479-85
pubmed: 19774334
Neurosurgery. 2016 May;78(5):638-46
pubmed: 26492428
Neurosurgery. 2008 Feb;62 Suppl 2:733-43
pubmed: 18596432
Otolaryngol Head Neck Surg. 1985 Apr;93(2):146-7
pubmed: 3921901
J Neurosurg Sci. 2009 Mar;53(1):7-11
pubmed: 19322130
J Neurosurg. 2015 Jan;122(1):4-23
pubmed: 25343186
Neurosurgery. 2012 Jan;70(1):32-9; discussion 39
pubmed: 21765282
Stereotact Funct Neurosurg. 2011;89(1):17-24
pubmed: 21124048
Acta Neurochir (Wien). 2011 Jan;153(1):62-7; discussion 67
pubmed: 20953804
J Neurosurg. 2004 Nov;101 Suppl 3:390-5
pubmed: 15537194
Neurosurgery. 2006 Aug;59(2):244-54; discussion 244-54
pubmed: 16883165
Int J Radiat Biol. 2018 Jul;94(7):621-627
pubmed: 29775403

Auteurs

V Pinzi (V)

Neurosurgery Department, Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. valentinapinzi@yahoo.it.

M Marchetti (M)

Neurosurgery Department, Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

E De Martin (E)

Health Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

V Cuccarini (V)

Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.

I Tramacere (I)

Department of Research and Clinical Development, Scientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

F Ghielmetti (F)

Health Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

M L Fumagalli (ML)

Health Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

C Iezzoni (C)

Neurosurgery Department, Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

L Fariselli (L)

Neurosurgery Department, Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH